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INTRODUCTION
The essential role of innate immunity in elimination of pathogens is reflected by its remarkable existence and diversity at every level of the evolutionary tree of life. Indeed, plants and invertebrates rely solely on their innate immune system to eliminate infectious agents (Netea et al., 2016 (Netea et al., , 2011 . Similarly, innate immunity in vertebrates is often sufficient to eradicate many pathogens. One of the ancient cellular compartments of innate immunity with profound capacity to both recognize and destroy microorganisms is the mononuclear phagocyte system. Mycobacterium tuberculosis (Mtb) evolved multiple strategies to subvert or subdue the innate immune mechanisms to bypass its early elimination. Although we and others have previously shown the critical role of macrophages in protective immunity to Mtb infection (Behar et al., 2010; Divangahi et al., 2009 Divangahi et al., , 2010 , harnessing the power of macrophages in vaccine development has yet to be realized (Divangahi and Behr, 2017) .
Innate immune cells have classically been thought to lack immunological memory. However, recent studies have challenged this dogma by demonstrating that innate immune cells can also develop enhanced resistance upon reinfection with the same or an unrelated pathogen, a phenomenon known as trained immunity (Netea et al., 2016; 2011) . This response is considered to be independent of adaptive immunity and driven by epigenetic modifications that influence gene expression in mononuclear phagocytes (Kleinnijenhuis et al., 2012; Saeed et al., 2014; Tribouley et al., 1978) . Considering the nature of monocyte/macrophage (Mo/Mac) differentiation, as well as their relatively short lifespan, it is unknown how these cells transmit their memory phenotype to their progeny and provide sustained protection. Thus, vaccine strategies targeting Mo/Macs have limited efficacy for generating long-term innate immune memory.
In contrast to Mo/Macs, hematopoietic stem cells (HSCs) are long-lived cells that mainly reside in the bone marrow (BM). HSCs are self-renewing and able to generate multipotent and lineage-committed hematopoietic progenitors that give rise to all cells of the mammalian blood system (Cabezas-Wallscheid et al., 2014) . While the rapid adaptation of HSCs to hematopoietic stress is well documented (Manz and Boettcher, 2014) , our understanding of the consequences of vaccination or inflammatory signals on HSCs is extremely limited. Although the exact cellular and molecular mechanisms involved in regulation of HSC granulopoiesis, monocytopoiesis, or lymphopoiesis are unknown, several studies indicate that sensing pathogens (legend continued on next page) through pattern-recognition receptors (PRRs) (e.g., Toll-like receptors [TLRs] and nucleotide-binding oligomerization domain [NOD] -like receptors) and signaling through cytokines (e.g., types I and II interferon [IFN] ) or growth factors (e.g., granulocyte-colony-stimulating factors [G-CSFs] and granulocytemacrophage-colony-stimulating factors [GM-CSFs] ) dictate a specific bias in HSCs via the assembly of unique sets of transcriptional networks (King and Goodell, 2011) . For instance, the transcription factors (TFs) interferon regulatory factor-8 (IRF8) or CCAAT-enhancer binding proteins (C/EBPb) have been associated with myelopoiesis (Wang et al., 2001) , while the expression of the TFs paired box-5 (Pax5) or the interferon regulatory factor-4 (IRF4) tend to promote lymphopoeisis (Lu, 2008) . Bacillus Calmette-Gué rin (BCG) vaccine has been shown to be efficacious in protecting against Mtb in early childhood and, more interestingly, at decreasing overall morbidity and mortality to other infectious diseases, suggesting that the protective mechanism of BCG is not limited to only tuberculosis (TB) (Garly et al., 2003) . Given the level of cross-protection provided by BCG and the fact that BCG can be used to train Mo/Macs ex vivo (Cheng et al., 2014; Saeed et al., 2014) , we hypothesized that BCG can ''educate'' HSCs in the BM to generate Mo/Macs that are protective against subsequent infection with Mtb. Here, we show that access of BCG to the BM has a profound effect on the transcriptomic landscape of HSCs and MPPs and enhances myelopoiesis. These changes drive the hematopoietic system to generate ''trained'' Mo/Macs with a unique transcriptomic/epigenomic signature that is associated with long-term innate immune protection against Mtb infection.
RESULTS

Intravenous BCG Vaccination Triggers HSC Expansion
We vaccinated wild-type (WT; C57BL/6J) mice intravenously (iv) or subcutaneously (sc) with BCG-TICE strain, the clinical vaccine strain used in North America. After BCG-iv vaccination, BCG reached the BM, where it was detected up to 7 months post vaccination (Figure 1A) . The number of BCGs in the BM directly correlated with the expansion of the HSC progenitor lineage À c-Kit + Sca-1 + (LKS +) population (Figure 1B) . In contrast, BCGsc vaccinated mice rarely led to detectable levels of bacteria in their BM and failed to increase the number of LKS + cells. We next used image stream analysis to investigate whether BCG directly infects HSCs. Consistent with previous reports (Baldridge et al., 2010; Kolb-Mä urer et al., 2002) , we found that BCG was unable to infect HSCs either in vitro or in vivo, whereas BCG-infected Mo/Mac lineage cells were readily observed . Thus, the expansion of the LKS + population is not a consequence of direct infection with BCG. Since the peak of the LKS response occurred at 4 weeks post BCG-iv vaccination (Figure 1B) , we next characterized hematopoietic stem and progenitor cells at this time point. Specifically, we measured the proportions of long-term HSCs (LT-HSCs; LKS+CD150+CD48À), short-term HSCs (ST-HSCs; LKS+CD150+CD48+), and multipotent progenitors (MPPs; LKS+CD150ÀCD48+) ( Figures 1F-1I and S1). A significant increase of both ST-HSCs and MPPs was observed in BCG-iv vaccinated mice as compared with BCG-sc vaccinated mice or control (PBS-iv) mice (up to a 20-fold increase; Figure 1I ). Kinetic analysis of the BM-LKS + population showed that the increased LKS population in BCG-iv vaccinated mice was largely due to an increase in ST-HSCs and MPPs ( Figures  1J-1M ). Collectively, these data indicate that infection of the BM by BCG induces HSC expansion in trans and promotes their expansion and differentiation.
BCG Reprograms HSCs in the Bone Marrow and Enhances Myelopoiesis
To understand the impact of BCG on LKS population, we next performed bulk RNA sequencing (RNA-seq) on HSCs (LKS+CD150+) and MPPs (LKS+CD150À) isolated from the BM of BCG-iv vaccinated or control (PBS-iv) WT mice (Figures 2  and S2 and Table S1 ). The first principal component (PC1) of the resulting gene expression data accounted for 35.4% of the variance in our dataset and separated the LKS population from BCG-iv vaccinated mice and control (PBS-iv) mice (Figure 2A ; t test, p = 2.5 3 10 À7 ), while PC2 separated HSCs from MPPs (Figure 2A; 28 .3% of the overall variance, t test p = 6.5 3 10 À5 ). Accordingly, we found extensive differences in the gene expression levels between BCG-iv vaccinated mice and controls, with 3,914 (30%) and 4,774 (37%) differentially expressed genes in HSCs and MPPs, respectively (see STAR Methods and Table S2 ; false discovery rate [FDR] < 0.01). Genes differentially expressed between BCG-iv vaccinated mice and control mice in HSCs were also often differentially expressed in MPPs (Figure 2B ; 40.6% overlap, Fisher's exact test: odds ratio 3.08, p < 2.2 3 10 À16 ), suggesting that the transcriptomic changes observed in HSCs propagated to MPPs. Genes upregulated in both HSCs and MPPs of BCG-iv vaccinated mice were strongly enriched for gene sets involved in DNA replication, cell division and cell cycle (Figure 2C ; FDR % 1.1 3 10
À10
; Table S3 ), showing that BCG-iv vaccination remarkably increased the proliferative activity of LKS + cells. Indeed, virtually all key regulators of cell cycle progression (Cdk1 and Cdk4) and other cyclins (Ccng1, Ccnf, Ccne2, Ccne1, Ccnc, and Ccnb1) were strongly upregulated in HSCs and MPPs of BCG-iv vaccinated mice as compared with HSCs and MPPs from control mice ( Figure 2D ). Our data additionally showed that BCG-iv vaccination induced distinct regulatory networks that promoted the polarization of MPPs towards myelopoiesis at the expense of lymphopoiesis. Indeed, most genes involved in lymphocyte B and T cell differentiation were downregulated in HSCs and MPPs from BCG-iv vaccinated mice ( Figure S3A and Table S3 ). These genes In the x axis, we plot the quotient of the log2 fold-change response to BCG-iv vaccination in our data and the log2 fold-change between MPP3 and MPP4 reported by Cabezas-Wallscheid et al. (2014) . Tables S2 and S3. included several critical lymphoid-lineage markers (Lck, Rag1, and Rag2) and lymphoid TFs (Pax5 and Irf4) ( Figure 2D ). In contrast, myeloid-lineage TFs (e.g., Cebpe, Cebpa, and IRF8) and key cytokine-cytokine receptor pairs necessary for the generation of Mo/Macs (e.g., Csf1r and Csf2rb) were consistently upregulated in LKS + cells of BCG-iv vaccinated mice, particularly in MPPs ( Figure 2D ). We next compared our data with results from a previously published RNA-seq dataset on MPPs polarized towards the myeloid (MPP3) and lymphoid (MPP4) lineages (Cabezas-Wallscheid et al., 2014) . We found that MPPs from BCG-iv vaccinated mice more closely resembled the expression profiles of MPP3 (relative to MPPs from PBS control mice, p < 2.2 3 10 À16 , Figure 2E ) and that the changes in gene expression observed between BCG-iv and PBS-iv vaccinated mice were strikingly similar (83% concordance) to those observed between MPP3 and MPP4 (Figure S3B ) in non-vaccinated, BCG-sc vaccinated, or BCG-iv vaccinated mice. In accordance with transcriptomic analyses, MPP3, but not MPP4, was significantly increased in BCG-iv vaccinated mice ( Figures 2F-2H ). By contrast, there was no difference in these populations between non-vaccinated (PBS) or BCG-sc vaccinated mice. Collectively, these data indicate that access of BCG to the BM induces LKS expansion and promotes their differentiation into progenitors with restricted myeloid-lineage potential.
We next used droplet-based single-cell RNA sequencing (scRNA-seq) (Zheng et al., 2017) to ask how individual cells in the BM respond to BCG-iv vaccination. Following extensive quality control and filtering ( Figure S4A ), a total of 7,350 highquality LKS + cell transcriptomes (5,557 derived from PBS-iv control mice and 1,793 derived from BCG-iv vaccinated mice) were analyzed and clustered using Seurat (Satija et al., 2015) . To visualize the different clusters, we used t-distributed stochastic neighbor embedding (t-SNE) (Figure 3A Figure S4F and Table S4 ), one cluster of lymphoid-biased progenitors (MPP4), and three clusters of myeloid-biased progenitors (MPP3.C1, MPP3.C2, and MPP3.C3). The MPP3.C3 is characterized by the high expression of several granulocytic markers, including Ctsg, Mpo, and Elane ( Figure S4G and Table S4 ). We found extensive differences in gene expression across all six clusters when comparing cells derived from BCG-iv vaccinated mice and controls (Table S4) . Cells of the HSC1 cluster were the most responsive to BCG-iv vaccination, with 1.77-to 6.31-fold more differently expressed genes (5,037 DE genes; FDR < 1%) than cells belonging to the other clusters ( Figure 3B ). Overall, we found strong concordance in the response to BCG iv across cells belonging to the different lineages (average correlation in response r = 0.746; Figure S4H ). However, some marked differences were also apparent. For example, genes involved in response to bacteria or cytokines, as well as antigen processing and presentation, were strongly enriched among genes upregulated in MPPs, specifically in MPP3.C2, but to a much lesser extent in HSCs ( Figure 3C and Table S5 ).
Like with the patterns observed in the bulk RNA-seq data (Figures 2C and 2D) , we found that the key TFs involved in the response to IFNg (e.g., Stat1 [ Figure 3D ] or Irf1 [ Figure S4I ]) were significantly upregulated in the majority of clusters. These results indicate that IFNg signaling is critical for the priming and expansion of the LKS population. Consistent with this hypothesis and published reports (Baldridge et al., 2010; Belyaev et al., 2010) , IFNg-receptor-deficient (IFNgR À/À ) mice failed to expand the BM LKS population following BCG-iv vaccination ( Figure 3E ).
BCG-Trained Macrophages Confer Enhanced Protection against Mtb
Considering that BM-derived macrophages (BMDMs) are critical in immunity to Mtb infection (Pai et al., 2016) , we investigated whether the BCG-induced changes at the level of HSCs and MPPs could alter the antimycobacterial properties of Mo/Macs derived from the BM. To do so, we generated BMDMs from the BM of either control (PBS-iv) or 1, 2, and 5 months BCG-iv or BCG-sc vaccinated WT mice. These BMDMs were free of any viable BCG or BCG-derived products ( Figures S5A-S5C ). BMDMs were then infected with a virulent strain of Mtb (H37Rv; MOI 1), and their protective capacity was assessed after 4 hr, 3 days, and 5 days of infection ( Figure 4A ). Macrophages derived from the BM of mice vaccinated with BCG-iv, but not BCG-sc, demonstrated significantly better protection against Mtb challenge (Figures 4B and S5D) . To ensure that the protective phenotype of BMDMs from BCG-iv vaccinated mice did not require continuous exposure of the BM cells to BCG, mice vaccinated with BCG (iv or sc) or control (PBS-iv) were treated with the antimycobacterial drugs isoniazid (INH) and rifampicin (RIF), which eliminated virtually all bacteria from the BM (Figure S5E ). While the frequency of LKS+ cells decreased to the level of non-vaccinated mice (Figure S5F) , the protective capacities of BMDMs from BCG-iv vaccinated and INH-/RIF-treated mice against in vitro infection with Mtb remained completely intact ( Figure 4C ). These protective effects were dependent on IFNg signaling, as no protection was afforded in BMDMs from BCG-iv vaccinated IFNgR À/À mice ( Figure 4D ). These data indicate that the protective capacity of macrophages derived from educated HSCs/MPPs do not require the continuous presence of BCG in the BM. To characterize the molecular basis underlying the enhanced protective capacity of BMDMs derived from BCG-iv vaccinated mice, we used RNA-seq to profile gene expression levels in BMDMs from non-vaccinated or BCG-iv vaccinated mice prior to or after in vitro infection with Mtb. We found that Mtb infection exacerbated the gene expression differences observed between BMDMs from BCG-iv vaccinated and control mice. Indeed, we identified 6.5-fold more genes differently expressed between BMDMs generated from BCG-iv vaccinated mice and control mice following Mtb infection in comparison with cells from uninfected mice (2,757 versus 426 genes, FDR < 0.01; Figures S5G  and S5H ). Accordingly, we identified 2,395 genes (FDR < 5%) for which the intensity of the response to Mtb infection varied depending on vaccination status (hereafter referred to as ''differently responsive [DR] genes''; Figure 4E and Table S2) , with a stronger overall response in BMDMs from BCG-iv vaccinated mice (Mann-Whitney test; p < 2.2 3 10 À16 ; Figure S5I ). These results suggest that BCG-iv vaccination rewires the immune response of BMDMs. We next stratified DR genes into four classes based on the direction of the response to Mtb infection (i.e., up-or downregulated genes in response to Mtb) and the direction of the BCGvaccination effect (i.e., whether BMDMs from BCG-iv vaccinated mice showed an enhanced or dampened transcriptional response to Mtb infection) (Figure 4F See also Figure S4 and Tables S2, S4 , and S5. Figure 4F ) were specifically enriched for binding sites of most IFN regulatory factor (IRF) family members (IRF2, IRF7, and IRF9), STAT1 and STAT2 family members, and the IFNb regulator PRDM1 ( Figure 4G and Table S6 ). Additionally, genes showing the gene expression pattern II in BMDMs (i.e., more strongly upregulated in response to Mtb in the BCG-iv group) were enriched among genes that are upregulated in LKS + cells of BCG-iv vaccinated mice ( Figure 4H ), suggesting that the differences in immune responses observed at the level of BMDMs derive from BCG-induced transcriptional changes in HSCs. These results suggest that the increased protection afforded by BMDMs from BCG-iv vaccinated mice against Mtb infection is due to their ability to engage a stronger antimicrobial response, partly driven by IFN-related signaling.
BCG Induces Epigenetic Modifications in Macrophages
Next, we collected ChIP-seq data for three histone marks (H3K4me1, H3K4me3, and H3K27ac) in non-infected and Mtbinfected BMDMs (Table S1 ) derived from BCG-iv or PBS-iv mice. We focused the analyses on non-infected BMDMs to test for a link between epigenetic priming (i.e., baseline changes) and variation in transcriptional responses to infection resulting from BCG vaccination. The histone mark H3K27ac changes the most between BMDMs generated from BCG-vaccinated and PBS-control mice. We found 3,743 peaks-associated with 2,483 genes-that show significant (FDR < 5%) gain or loss of H3K27ac in BMDMs from BCG-iv vaccinated mice compared to PBS-iv mice (Table S7 ). These changes primarily occurred outside promoter regions ( Figure 5A ) and in regions showing high levels of H3K4me1 ( Figure 5B ), suggestive of putative enhancer elements. For H3K4me3, we found a total of 2,463 peaks that were responsive to BCG-iv vaccination at a more relaxed FDR of 20%. Interestingly, genes near condition-specific regulatory elements (i.e., regions of the genome that are differentially marked by H3K4me3 and/or H3K27ac in BMDMs from BCG-iv vaccinated versus PBS-control mice) were also significantly enriched in genes that respond differently to Mtb infection in BCG-iv vaccinated versus PBS-control mice ( Figures 5C-5E ). Genes near peaks changing H3K4me3 and H3K27ac levels were significantly enriched for GO terms also associated with genes showing an enhanced response to Mtb infection in BMDMs from BCG-iv vaccinated mice compared to PBS-control mice ( Figure 5F and Table S8 ). These results indicate that even prior to Mtb challenge, BMDMs from BCG-iv vaccinated mice are epigenetically primed to initiate a more protective response against Mtb infection, which is, at least in part, due to the poised/active state of key enhancer elements. Figure 6B ) and lung macrophages ( Figure 6C ) in Ccr2 À/À parabionts were largely of WT (CD45.1 + ) origin at 4 weeks post Mtb infection. Importantly, BCG-iv vaccination of the CD45.1 + mice did not alter the frequency of monocytes in the blood compared with PBScontrol pairs ( Figure 6D ). Remarkably, lung histology demonstrated fewer bacteria and less inflammation in Ccr2 À/À mice paired with BCG-iv vaccinated mice compared to PBS-treated controls ( Figure 6E ). Accordingly, the Mtb burden was significantly lower in the lungs of Ccr2 À/À mice paired with BCG-iv vaccinated mice ($10-fold difference; Figure 6F ). Similar results were obtained in INH-/RIF-treated mice prior to surgical joining with Ccr2 À/À mice ( Figure 6G ). Together, these data demonstrate that BCG-iv vaccination intrinsically enhances the antimycobacterial capacity of BM-derived monocytes and macrophages that ultimately migrate to the lung and provide protection against virulent Mtb infection.
HSC Education Is Sustainable and Does Not Require Persistent Exposure to BCG To directly assess whether HSC reprogramming was sustained independent of continued exposure to BCG, we generated chimeras in which lethally irradiated mice received BM from BCG-iv vaccinated or unvaccinated donors ( Figure 7A ). Chimeric (F) Four subclasses of DR genes were defined: pattern I genes that were upregulated in response to Mtb infection and showed a weaker response in BMDMs from BCG-iv vaccinated mice (n = 254), pattern II genes that were upregulated in response to Mtb infection and showed a stronger response in BMDMs from BCG-iv vaccinated mice (n = 727), pattern III genes that were downregulated in response to Mtb infection but showed a stronger downregulation in BMDMs from BCG-iv vaccinated mice (n = 737), and pattern IV genes that were downregulated in response to Mtb infection but showed a weaker downregulation in BMDMs from BCG-iv vaccinated mice (n = 172). within patterns II and III described in (F) (enhanced upregulation and enhanced downregulation, respectively).
In panels (G) and (H), error bars show 95% confidence intervals for the enrichment estimates. In panels (B)- (D), we show: mean + SEM. *p % 0.05, ***p % 0.001, ****p % 0.0001 (two-way ANOVA). See also Figure S5 and Tables S2 and S6 . See also Tables S3, S7 , and S8.
mice were treated with antibiotics to ensure complete elimination of BCG in the BM ( Figure 7B ). The frequency of the LKS population as well as the total number of macrophages and T cells in the lungs were similar between the two groups of chimeric mice at 14 weeks post BM transplantation ( Figures  S6A-S6C ). Next, chimeric mice were infected with a low dose of aerosolized Mtb (H37Rv; $50 CFU per mouse). At 4, 8, and 20 weeks post Mtb infection, the number of bacteria in the lungs was significantly lower in chimeric mice that had received BM from BCG-iv vaccinated mice compared with PBS controls (Figure 7C) . To show that this protection was mainly mediated by educated HSCs/monocytes/macrophages and not BM-residential memory T cells (Di Rosa and Gebhardt, 2016), we repeated the experiment by generating chimeric mice with T cell-depleted BM from BCG-iv vaccinated and PBS-treated control mice . Chimeric mice generated with BCG-iv BM without T cells again showed significantly enhanced protection against Mtb infection compared with control mice ( Figures   7D-7F ). Importantly, the increased protection observed in the chimeric mice derived from BCG-iv vaccinated mice was not a reflection of increased frequencies of LKS + cells in the BM or total macrophages and T cells in the lungs (Figures 7G, 7H, S6G, and S6H) . These data indicate that macrophages derived from the BM of BCG-iv vaccinated mice are intrinsically imprinted with an enhanced capacity to control the growth of Mtb. Finally, to directly address whether BCG-iv vaccination educates HSCs to generate trained Mo/Macs with enhanced anti-Mtb function in vivo, we generated BMDMs from either non-vaccinated or BCG-iv or BCG-sc vaccinated mice. We then infected these macrophages with Mtb in vitro and adoptively transferred them (intratracheally) into Rag1-deficient mice ( Figure 7I ). Importantly, the numbers of bacteria in BMDMs of all three groups were almost identical prior to adoptive transfer into recipient mice ( Figure S6I ). 4 weeks after adoptive transfer, Rag1 À/À mice that had received Mtb-infected BMDMs from BCG-iv vaccinated mice showed significantly lower Mtb burden in both the lung and spleen than Rag1 À/À mice that had received Mtb-infected BMDMs from BCG-sc vaccinated or non-vaccinated mice showed (Figures 7J and 7K ). These data collectively indicate that BCG imprints HSCs to generate macrophages with enhanced antimycobacterial capacity.
DISCUSSION
In the current study, we define a mechanism by which HSCs can be educated to imprint mononuclear phagocytes to maintain their memory-like protective capacity against a virulent bacterial pathogen. Specifically, the initial presence of BCG in the BM was required for the priming of HSCs, whereas upon subcutaneous vaccination, BCG had no access to BM and thus, no effects on HSCs. In addition, the protective capacity of (Zhao et al., 2010) . Thus, the context of HSC exposure to IFNg (e.g., infection versus non-infection), as well as the magnitude and duration of IFNg signals, is likely to regulate the HSC response. Consistently, we found that IFNg signaling was essential not only for the expansion of the LKS population, but also for the generation of trained Mo/Macs. Although we have identified several cytokine and TF networks in HSCs that drive lineage commitment, the underlying regulatory mechanisms remain largely unknown. Thus, further studies are required to identify other cytokine pathways or PRRs that are triggered by BCG to generate educated HSCs. Nevertheless, our results demonstrate that transcriptional changes incurred by BCG vaccination at the level of HSCs can be ''transmitted'' to MPPs and BMDMs, leading to an enhanced protective capacity against Mtb infection. Our data indicate that such increased protection is likely afforded by epigenetic changes-notably, changes in the activation of enhancer elements-that prime trained BMDMs to engage an enhanced response to Mtb infection. Such epigenetic alterations ultimately lead to increased expression upon infection of several cytokines essential for protective antimycobacterial immunity, such as IFNg, tumor necrosis factor (TNF)-a, and interleukin (IL)-1b. This increased transcriptional response appears to be dependent on the activity of IRF and STAT TFs, further highlighting the importance of IFN regulatory networks in macrophage training.
Several studies (Anacker et al., 1972; Barclay et al., 1970 Barclay et al., , 1973 Sharpe et al., 2016) have shown that BCG-iv vaccination in non-human primates provided significantly better protection against Mtb infection than BCG-intradermal vaccination. These studies not only support our observations, but also provide a rationale for evaluating BCG-iv vaccination strategies in humans. It is also important to note that BCG vaccination in children is currently administered intradermally, and its protection efficacy ranges from 0% to 80% against pulmonary TB in adults (Brewer, 2000; Curtis et al., 1984; Hart and Sutherland, 1977) . It is thus tempting to speculate that this variability might be due to the inconsistent ability of BCG to access the BM in newborns (Divangahi and Behr, 2017) .
Although control of TB requires T cells to prevent disease progression, clinical trials that tested T cell-targeted vaccines have failed to demonstrate protection against Mtb infection (Tameris et al., 2013) . In addition, hyper-conserved Mtb genes involved in the production of immunodominant T cell epitopes have recently been described indicating that Mtb may paradoxically benefit from recognition by T cells (Comas et al., 2010) . These results suggest that the concept of vaccines aimed at generating robust memory T cell responses for protection against TB needs to be revisited. Here, we show the power of HSCs to generate innate memory responses. Identifying a protective HSC signature may provide a novel approach for targeting innate immunity to develop better vaccines against TB and other infectious diseases.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
Six-to ten-week old C57BL/6J, Rag1
, Ccr2 -/-, IFNgR -/-, and CD45.1 + B6 mice were purchased from Jackson Laboratories or bred at the RI-MUHC, Montreal, QC, Canada. All experiments were performed with male mice, except parabiosis, which was performed on female mice. All animal studies were conducted in accordance with the guidelines of and approved by the Animal Research Ethics Board of McGill University (project ID: 5860). Mice were housed under SPF conditions with ad libitum access to food and water, and were randomly assigned to experimental groups.
METHOD DETAILS
Bacterial culture BCG-TICE and Mtb H37Rv were grown in 7H9 broth (BD) supplemented with 0.2% glycerol (Wisent), 0.05% Tween80 (Fisher), and 10% albumin-dextrose-catalase (ADC) under constant shaking at 37 C. BCG-GFP was generously provided by Dr. Marcel Behr (McGill University) and grown in 7H9 broth (BD) supplemented with 0.2% glycerol (Wisent), 0.05% Tween80 (Fisher), 10% ADC, and 25mg/ml Kanamycin (Wisent) under constant shaking at 37 C. For in vitro and in vivo experiments, bacteria in log growing phase (OD 0.4 -0.9) were centrifuged (4000 RPM, 15 minutes) and resuspended in RPMI without penicillin/streptomycin or sterile PBS. Single cell suspensions were obtained by passing the bacteria 10-15 times through a 22G needle (Terumo).
In vivo experiments
Vaccination of mice Throughout the study, mice were intravenously (iv) or subcutaneously (sc) vaccinated with 1x10 6 single-suspended BCG in 100ml PBS, unless otherwise indicated. Antibiotics treatment of mice For antibiotics treatment with antimycobacterial drugs, the drinking water of the mice was supplied with 100mg/L Isoniazid (INH; Sigma-Aldrich) and 100mg/L Rifampicin (RIF; Fisher) for four weeks. The antibiotics treatment was followed by a two-week wash-out period on regular water.
Mtb infection of mice
Mice were either infected with $50 CFU of Mtb H37Rv in a nose-only aerosol exposure unit (Intox), or with H37Rv ($1000 CFU) via intratracheal instillation using a 22G catheter (BD). Infection dose was confirmed by enumerating the lung CFU one-day after infection. Adoptive Transfer Model C57BL/6J mice were vaccinated (iv or sc) with BCG-TICE (1x10 6 CFU) or PBS-injected (PBS-iv). After four weeks, BM cells were harvested and BMDMs were generated as described below. BMDMs were infected with H37Rv (MOI of 0.5) for 30 minutes at 37 C and 5% CO 2 with frequent agitation. Free bacteria were then removed by washing 5x with cold RPMI, each followed by centrifugation (1500 RPMI) for 10 min at 4 C. BMDMs (0.5x10 6 cells) were resuspended in 40ml PBS and then intratracheally transferred into naive Rag1 -/-mice (Divangahi et al., 2009; 2010) . The initial number of bacteria prior to transfer was assessed by plating H37Rv-infected macrophages on 7H10 agar plates. Parabiosis Parabiosis was performed as previously described (Ensan et al., 2016 were depleted from the BM by FACS sorting prior to transplantation. Mice were kept under antibiotic treatment (0.5g Enrofloxacin (Bayer) per liter of drinking water) for three days before and two weeks after irradiation and reconstitution. Chimeric mice were aerosol infected with $50 CFU Mtb H37Rv after 14 weeks when the hematopoietic compartment was reconstituted as determined by flow cytometry and no BCG was detectable in the BM.
In vitro experiments
Generation of BMDMs Bone marrow from both femurs and tibiae was harvested in RPMI (Wisent) supplemented with 10% heat-inactivated FBS (Wisent). Cells were subsequently seeded in 7 ml RPMI supplemented with 2mM L-glutamine, 10% FBS, 2% HEPES, 1% non-essential amino acids, 1% essential amino acids, 0.14% 5N NaOH, 1mM sodium pyruvate, 100U/ml penicillin, 100mg/ml streptomycin (all Wisent), and 30% of L929-conditioned media (LCM) in petri dishes. After 3 days of incubation at 37 C with 5% CO 2 , fresh medium containing LCM was added. Cells were allowed to differentiate into macrophages for a total of 6 days and then were harvested by removing the supernatant and addition of 4ml cell stripper (Corning) for 20 minutes at 37 C. As evaluated by flow cytometry, the purity was usually around 99%. In vitro Macrophage Infection BMDMs (1x10 6 cells) were seeded in 6-well plates supplemented with RPMI without penicillin/streptomycin (1 ml), and incubated overnight at 37 C with 5% CO 2 . Next day, cells were infected with Mtb H37Rv (MOI 1), unless otherwise indicated. Cells were incubated for 4 hours at 37 C with 5% CO 2 . Subsequently, cells were washed 3x with sterile PBS, and were then incubated in supplemented RPMI without penicillin/streptomycin. CFUs were enumerated at 4 hours, day 3 and day 5 post infection, unless otherwise indicated.
CFU Enumeration
For CFU enumeration in in vitro infected cells, cells were harvested by scraping and centrifuged together with the supernatant (4000 RPM, 10 minutes). The pellet was lysed with 500ml sterile H 2 O for five minutes, followed by addition of 500ml PBS supplemented with 0.05% Tween80. For CFU enumeration in tissues, organs were homogenized in 1ml 7H9 broth (BD) supplemented with 0.2% glycerol (Wisent), 0.05% Tween80 (Fisher), and 10% ADC using OmniTip Plastic Homogenizer Probes (Omni International). Serial dilutions in PBS+0.05% Tween80 were plated on 7H10 agar plates with 10% OADC enrichment and PANTA (BD). Plates were then incubated at 37 C and counted after 21 days.
Flow Cytometry
Red blood cells were lysed in bone marrow and collagenase IV (Sigma)-treated lung samples. BM or lung cells (3x10 6 cells) were stained with fixable viability stain eFluor501 (eBioscience) at the concentration of 1:1000 for 30 minutes (4 C). Subsequently, the cells were washed with PBS supplemented with 0.5% BSA (Wisent) and incubated with anti-CD16/32 (clone 93, eBioscience) at a concentration of 1:100 in PBS/0.5% BSA at 4 C for 10 minutes. The following antibodies were then used for staining: Staining for LKS, HSCs, and MPPs: anti-Ter-119, anti-CD11b (clone M1/70), anti-CD5 (clone 53-7.3), anti-CD4 (clone RM4-5), antiCD8a (clone 53-6.7), anti-CD45R (clone RA3-6B2), and anti-Ly6G/C (clone RB6-8C5), all biotin-conjugated (all BD Bioscience), were added at a concentration of 1:100 for 30 minutes at 4 C. Cells were subsequently washed with PBS/0.5% BSA. Streptavidin -APC-Cy7 (eBioscience), anti-c-Kit -APC (clone 2B8, eBioscience), anti-Sca-1 -PE-Cy7 (clone D7, eBioscience), anti-CD150 -eFluor450 (clone mShad150, eBioscience), anti-CD48 -PerCP-eFluor710 (clone HM48-1, BD Bioscience), anti-Flt3 -PE (clone A2F10.1, BD Bioscience), and anti-CD34 -FITC (clone RAM34, eBioscience) (all 1:100) were added and incubated at 4 C for 30 minutes.
Staining for cells of the innate immune system: anti-F4/80 -APC-Cy7 (clone BM8, eBioscience), anti-Ly6C -APC (clone HK1.4, eBioscience) or FITC (clone AL-21, BD Bioscience), anti-Ly6G -PerCP-eFluor710 (clone 1A8-Ly6g, eBioscience) or Pe-Cy7 (clone 1A8, BioLegend), anti-SiglecF -PE-CF594 (clone E50-2440, BD Bioscience), anti-CD11c -BV421 (clone N418, BD Bioscience), anti-CD11b -PE-Cy7 (clone M1/70, BD Bioscience), anti-NK1.1 -BV650 (clone PK136, BD Bioscience) (all 1:200), and anti-CCR2 -PE (R&D systems, 1:100) were added for 30 minutes at 4 C. Staining for cells of the adaptive immune system: anti-CD19 -PE (clone 1D3, BD Bioscience), anti-CD3 -APC or BUV737 (both clone 145-2C11, BD Bioscience), anti-CD4 -FITC (clone H129.19, BD Bioscience), anti-CD8 -PE-Cy5 (clone 53-6.7, BD Bioscience), anti-CD127 -PE-Cy7 (clone A7R34, eBioscience), anti-CD44 -APC-Cy7 (clone IM7, BD Bioscience), and anti-CD62L -V450 (clone MEL-14, BD Bioscience) (all 1:100) were added for 30 minutes at 4 C. Staining for the blood leukocytes: 100 ml of whole blood collected in heparin tubes (BD) was incubated with anti-CD16/32 (clone 93, eBioscience, 1:300), anti-CD115 -PE (clone AFS98, eBioscience, 1:100), anti-CD3 -eFluor450 (clone 17A2, eBioscience, 1:200), anti-Ly6C -FITC (clone AL-21, BD Bioscience, 1:200), anti-Ly6G -AlexaFluor700 (clone RB6-8C5, eBioscience, 1:200), anti-CD11b -PE-Cy7 (clone M1/70, BD Bioscience, 1:200), anti-CD19 -APC-Cy7 (clone 1D3, BD Bioscience, 1:200), and anti-CCR2 -AlexaFluor594 (R&D systems, 1:100) at 4 C for 30 minutes. If required, panels were modified using anti-CD45.1 -APC (clone A20, BD Bioscience, 1:100) and anti-CD45.2 -BUV395 (clone 104, BD Bioscience, 1:100). All cells were subsequently washed with PBS/0.5% BSA and resuspended in 1% paraformaldehyde. Cells were acquired on BD flow cytometers (Canto II or Fortessa X-20) with FACSDiva Software. Analyses were performed using FlowJo software v.10.1 (TreeStar).
Cell Sorting
For stem cell sorting, BM cells were harvested from femurs, tibiae, humeri, and ossa ilii, and incubated with the described biotin-conjugated antibodies against lineage-committed cells. Subsequently, the cells were incubated with MACS streptavidinconjugated microbeads (Miltenyi) for 30 minutes at 4 C. A depletion of the lineage-committed cells was performed using AutoMACS (Miltenyi) to reduce the total cell number. The remaining cells were incubated with the above described antibodies for LKS/HSCs/MPPs. DApI (0.005mg) was added for viability staining to 10x10 6 cells right before sorting on a BD FACSAria Fusion sorter. Cells were sorted in 200ml lysis buffer of Magmax-96 Total RNA Isolation Kit (life technologies, Ambion 1830) at room temperature or in PBS containing 0.04% BSA for single cell sequencing. RNA samples were vortexed for 30 seconds, and subsequently stored at -80 C until RNA extraction. For T cell depletion, pooled BM cell samples were incubated with anti-CD3 antibody (APC, clone 145-2C11, BD Bioscience) and sorted as CD3 + and CD3 -samples.
ImageStream
For in vitro infection, freshly isolated BM cells from naïve C57BL/6J mice were infected with BCG-GFP (MOI 1) for 4 hours. For in vivo infection, C57BL/6J mice were vaccinated with BCG-GFP (10x10 6 ) and the BM was harvested at day 3 post vaccination. BM cells were then stained with the antibodies described for LKS and innate immune cells. Images were captured on an Amnis ImageStream Mark II Imaging Flow Cytometer with 40x magnification (EMD Millipore). Data were acquired and analyzed using Amnis INSPIRE software and Amnis IDEAS software, respectively.
Histopathology and bacterial staining
Post-caval lung lobes were fixed in 10% formalin. H&E staining for pathohistological analysis and Ziehl-Neelsen staining for acid-fast bacteria was performed by the Histopathology Core of RI-MUHC, Montreal, QC, Canada. qPCR RNA was extracted from BMDM of PBS-iv or BCG-iv vaccinated mice or from BCG cultures used as a positive control, using Trizol reagent (Qiagen), according to manufacturer's instructions. 500 ng of RNA was reverse transcribed using the 5X RT Mastermix (ABM). Expression levels of mycobacteria-specific sigA or bacterial 16S rRNA were determined by qPCR using EvaGreen (abm) using the following primers: sigA-forward: 5'-TCGCGCCTACCTCAAAC-3', sigA-reverse: 5'-CTAGCTCGACCTCTTCCTCGG-3', 16S rRNA-forward: 5'-GTGGAGAAGAAGCACCGGC-3', 16S rRNA-reverse: 5'-ACGCTCGCACCCTACGTATT-3' (Reed et al., 2007) , GAPDH-forward: 5'-GGTCCTCAGTGTAGCCCAAG-3'; GAPDH-reverse: 5'-AATGTGTCCGTCGTGGATCT-3' (Downey et al., 2017) . Ct values were obtained on CFX96 PCR System (Biorad) and relative expression was analyzed using the formula 2-DCt, where DCt = Ct-target gene BMDM ÀCt-target gene BCG for sigA and 16S rRNA analyses, and DCq = Cq-target gene BMDM BCG-iv ÀCq-target gene BMDM PBS-iv for GAPDH analysis. Bulk RNA-seq library preparation and sequencing Total RNA was extracted from the sorted HSCs and MPPs using Magmax-96 Total RNA Isolation Kit (life technologies, Ambion 1830M) or from BMDMs using the miRNA Easy kit (Qiagen). RNA quantity was evaluated spectrophotometrically, and the quality was assessed with the Agilent 2100 Bioanalyzer (Agilent Technologies). All samples showed RNA integrity number > 8. RNAsequencing libraries were prepared using the Illumina TruSeq protocol or the SMARTer Stranded RNA-Seq Kit (Clontech) for BMDMs and HSCs/MPPs, respectively. Once prepared, indexed cDNA libraries were pooled (6 libraries per pool) in equimolar amounts and were sequenced with single-end 100 bp reads on an Illumina HiSeq2500. Number of reads sequenced per sample can be found in Table S1 . Single cell RNA-seq library preparation and sequencing Single-cell GEMs were generated using a Chromium Controller instrument (10x Genomics). Sequencing libraries were prepared using Chromium Single Cell 3' Reagent Kits (10x Genomics), according to the manufacturer's instructions. Briefly, GEM-RT was performed in a thermal cycler: 53 C for 45 min, 85 C for 5 min. cDNA was cleaned up with DynaBeads MyOne Silane Beads (ThermoFisher Scientific) and amplified with a thermal cycler: 98 C for 3 min, cycled 12 x 98 C for 15 s, 67 C for 20s, 72 C for 1 min, and 72 C 1 min. After a cleanup with SPRIselect Reagent Kit, the libraries were constructed by performing the following steps: fragmentation, end-repair, A-tailing, SPRIselect cleanup, adaptor ligation, SPRIselect cleanup, sample index PCR, and SPRIselect size selection. Libraries were sequenced on an Illumina HiSeq 4000 with 100 bp paired-end reads. ChIP-seq library preparation and sequencing We collected ChIP-seq data for three histone marks (H3K4me1, H3K4me3, H3K27ac) in non-infected and Mtb infected BMDMs derived from BCG-vaccinated or PBS-control mice as we previously described (Pacis et al., 2015) . Samples from BCG-vaccinated and non-vaccinated, Mtb-infected and non-infected BMDMs were crosslinked with 37% w/v formaldehyde for 20 minutes at RT and immediately quenched for 5 minutes with 1M Glycine at RT. The formaldehyde fixed samples were then sonicated to 150-500 bp using an E220 sonicator (Covaris), and subsequently ChIP-DNA was prepared using a manual chromatin immunoprecipitation method with Antibodies-Antigen incubation for 18 hours, followed by bead incubation for 150 minutes, and 7 5-minute washing steps. Approximately 1x10 6 cells were used for each ChIP and $50,000 cells for the input. The following antibodies were used: ChIP and Input libraries were prepared using the MicroPlex Library Preparation Kit v2 (C05010013, Diagenode), with alterations including: PCR enrichment (9 to 18 cycles) prior to size selection, and use of Ampure beads for size selection (250-350 bp). Libraries were sequenced on an Illumina HiSeq 2500. We pooled 6 libraries per lane and each library was sequenced using 100 bp single-end reads. ATAC-seq library preparation and sequencing Chromatin accessibility was accessed using ATAC-seq (Buenrostro et al., 2013) . ATAC-seq libraries were generated from 100,000 BMDMs, and sequenced on an Illumina HiSeq 2500 using 100 bp paired-end reads. We performed ATAC-seq on noninfected BMDMs from four PBS-control mice and three BCG-iv vaccinated mice.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistics for mice work Statistical analyses were performed using Graph Pad Prism, version 6.0c. Data are displayed as mean ± SEM and n defines the number of animals analyzed per group. Statistical significance was determined by t test, 1-way, or 2-way ANOVA, as indicated in the figure legends, and is represented by the following scheme: * p%0.05, ** p%0.01, *** p%0.001, **** p%0.0001.
Multiple testing correction in differential expression analyses
Throughout the paper, differential expression FDRs were calculated according to the method proposed by Storey and Tibshirani implemented in the R-package qvalue (version 2.6.0 (Dabney et al., 2010)).
Gene ontology enrichments
We used the cytoscape app ClueGO (version 2.3.3) (Bindea et al., 2009 ) to identify Gene-Ontology terms enriched among genes showing DE patterns in either LKS + cells (bulk-RNAseq and single cell RNA-seq) or BMDMs (bulk RNA-seq or Chip-seq). The following parameters were used when running ClueGO, (unless otherwise stated): Min GO Level = 3; Max GO Level = 8; Minimum Number of Genes associated to GO term = 5; Minimum Percentage of Genes associated to GO term = 5. Enrichment p-values were based on a hypergeometric test and we used Benjamini-Hochberg method for multiple testing correction.
In LKS + cells, we analyzed the bulk-RNAseq data, and tested for GO enrichments among genes showing a coherent, shared effect due to BCG-iv vaccination in both cell types analyzed (MPPs and HSCs, FDR <0.01 for both), either towards gene up-regulation (n=1,325) or down-regulation (n=1,112) in BCG-iv vaccinated mice compared with control mice. In this case, to restrict more the number of terms enriched, we raised the minimum number/percentages of genes per terms to 15 / 15%. Results of these analyses are reported in Table S3 , and summarized in Figure 2 .
Then, we complemented this view in the single cell LKS + RNA-seq dataset, where GO enrichment analyses were conducted on genes up-regulated by BCG-iv in each of of the six clusters found. The equally-sized target gene sets were defined as the top 1000 most significantly up-regulated genes per cluster, which corresponds to FDR thresholds of 8.0x10 -8 (HSC1), 5.2x10 -4 (HSC2), 4.9x10 -3 (MPP3.C1), 9.5x10 -3 (MPP3.C2), 0.14 (MPP3.C3), and 0.03 (MPP4)). The results of these analyses are reported in Table S5 , and summarized in Figure 3C , where we show all the terms enriched at FDR=1E-8 and with more than n=15 genes in the target gene set in at least one of the six clusters. GO terms were stratified using hierarchical clustering for visualization. For BMDMs, we focused on genes showing an interaction between vaccination status and transcriptional response to Mtb infection. This corresponds to genes for which the response to Mtb infection is significantly impacted by BCG-iv vaccination. We classified significant interactions at an FDR < 0.05. These genes were further classified into four groups with respect to their altered response in BCG-iv vaccinated mice (see Figure 4F ): I: dampened up-regulation (n=254), II. Enhanced up-regulation (n=727), III. Enhanced downregulation (n=737), and IV. dampened down-regulation (n=172). GO-enrichment analyses were performed for each of these gene sets. Specifically, we tested for functional enrichments among genes belonging to patterns I and II with respect to a background composed of all genes that were upregulated by Mtb in PBS-control samples (FDR <0.01, n=3, 290) . Then, we performed the complementary analyses and tested for ontology enrichments among genes in patterns III and IV, with respect to a background composed of genes down-regulated upon Mtb infection in PBS-control samples (FDR <0.01, n=3, 384) . Results of these analyses are presented in Table S3 .
For H3K27ac and H3K4me1, we performed differential-peak analyses comparing BCG-iv vs PBS-iv before infection. We then associated each peak to its nearest protein-coding gene and selected the most significant event for each gene. The 1000 genes showing the most significant nearest-peak effects were selected as targets for ontology enrichment analysis, which corresponded to FDR thresholds ranging from 0.007 (H3K27ac) to 0.18 (H3K4me3). The complete results of these analyses are detailed in Table S8 . In Figure 5F , we show the top 20 GO terms most enriched among genes showing changes in each of the histone marks, which are also enriched in some of the different expression patterns of BMDMs.
Bulk RNA-sequencing Data pre-processing A total of n=32 bulk RNA-seq samples were processed in this study. Adaptor sequences and low quality score bases (Phred score < 20) were first trimmed using Trim Galore (version 0.2.7). The resulting reads were then mapped to the mouse genome reference sequence (GRCm38/mm10 Ensembl release 81) using the alignment software STAR (version 2.4.2) (Dobin et al., 2013) . Gene-level expression estimates were calculated using featureCount (from the subread package version 1.4.4) (Liao et al., 2014) .
We generated 16 RNA-seq libraries of HSCs (LKS + CD150 + ) and MPPs (LKS + CD150 -) from the BM of mice either vaccinated with BCG intravenously or with PBS (i.e., control mice). After quality control of the data we excluded one sample that was a clear outlier in the PCA analyses leaving a total of 15 samples for downstream analyses. For BMDMs, we collected 16 RNA-seq samples corresponding to non-infected BMDMs and BMDMs infected with Mtb for 24 hours, derived from 4 BCG-iv vaccinated mice and 4 PBS-control mice. For all downstream analyses, we excluded lowly-expressed genes, by only including genes showing a median log2(cpm) of 2 in at least one of the treatment-cell type combinations. This yielded n=13,072 genes in the LKS + dataset, and n=10,188 genes in BMDMs.
Identification of differently expressed genes between experimental conditions
Gene expression levels across samples were normalized using the TMM algorithm (i.e., weighted trimmed mean of M-values), implemented in edgeR R package (version 1.16.5 (Robinson et al., 2010) ). Afterwards, we log-transformed the data and obtained precision-weights using the voom function in the limma package (version 3.30.13 (Ritchie et al., 2015) ). Finally, we performed a weighted fit using lmFit (also from limma) and the weights obtained from voom.
In order to interrogate for BCG effects in HSCs and MPPs, we used a nested linear model with the following design: Expression $ Cell_type + BCG:Cell_type, which captures independently the treatment effects on gene expression observed in the two cell lines analyzed (HSCs and MPPs). Likewise, in BMDMs, we used a nested linear design: Expression $ Infection + BCG:Infection that we used to capture, independently, BCG-iv effects in non-infected and Mtb-infected BMDMs. In addition, for the identification of genes showing significant differences in the transcriptional response to Mtb infection between BCG-iv vaccinated mice and PBS-controls (DR genes), we fitted the following linear model that takes into account the paired nature of our experiment: Expression $ Individual + Infection:Treatment. From this model we extracted: 1. Mtb infection effects in PBS-injected mice; 2. Mtb infection effects in BCG-iv vaccinated mice; and 3. Difference between infection effects in BCG-iv vaccinated and PBS-injected mice (infection X treatment interactions).
Nominal p-values provided by lmFit were corrected for multiple testing using the R package qvalue (version 2.6.0 (Dabney et al., 2010) ). The complete results of these DE analyses are reported in Table S2 .
Single cell RNA-sequencing scRNA-seq data pre-processing and quality control Sample preprocessing was done using the count command of CellRanger (Zheng et al., 2017) against the mm10 1.2.0 reference genome. As part of the different QC filters, we filtered out cells (i) expressing less than 500 genes, (ii) with an high fraction of mitochondrial RNA reads ðf mito >4.7%), (iii) with a low number of UMIs (n UMI <2400), or (iv) with a low percentage of protein-coding genes (f pc <92.5%) (these thresholds were set upon visual inspection; Figure S4A ). After these QC steps we kept a total of 7,666 cells (5, 872 and 1, respectively) .
In addition to removing lower quality cells, we limited all downstream analyses to genes that were expressed in at least 5 cells, corresponding to 14,752 genes. scRNA-seq data normalization We used the function computeSumFactors, from the R package scran (Lun et al., 2016) to normalize the data. This method works by declaring a series of cell pools whose expressions are added and normalized against a common reference. Each of these pools is then interpreted as a linear system from which the contribution of each single cell can be deconvolved, allowing the inference of cellwise normalization factors in a way that is robust against noise and low expression levels. To ensure that a majority of genes are not DE between any of the pools and the common reference that they are normalized against, clusters of homogeneous gene expression are first built using the function quickCluster. Thus, cell specific normalization factors are inferred within each cluster, and then rescaled by normalization between clusters. Correcting for variation in cell cycle in single cell data Cell cycle numeric scores were inferred for each cell using the function cyclone implemented in package scran (Lun et al., 2016) . The method is based on a pre-defined classifier constituted by gene pairs whose relative difference in expression depends on the cell cycle stage. By comparing the coherence of the sign of the differences observed in the data to the classifier's expectation, per-cell scores were obtained for phases G1 and G2M. These values were summarized as a single numeric score C = ðG1 À G2MÞ=ðG1 + G2MÞ, which we mean centered and scaled across cells. These scores were corrected for at the steps of expression data scaling and cell clustering. Single cell data scaling Once the data was normalized, we fitted for each gene the following linear model:
The residual variance derived from this model was then fitted against mean expression of the corresponding genes using the scran's loess smoothing function, trendVar (parameters: trend=loess, span=0.1, degree=2). The deviations from the inferred trend were computed per gene using scran's function decomposeVar. Then, the first decile corresponding to the genes showing the largest, negative deviations from the fitted trend were selected, and the procedure was repeated. By doing so, we obtained an unbiased basal trend for the technical component of the residual variance that is not affected by the outliers with variance much larger than the technical variance. Finally, we calculated the biological component of the variance as the difference between the residual variance and the basal technical component (s 2 ε = s 2 tech + s 2 bio , Figure S4B (i) ). Once the variance decomposition was done, the scaled expressionẼ was defined by rescaling the residuals of Equation 1 by the square-root of the technical component of the residual variance:
Through these procedures, the mean-variance relationship was successfully removed from the data, as illustrated in Figure S4B (ii). Selection of the set of relevant genes for dimensionality reduction We defined a set of 101 highly-informative genes that we used for single cell dimensionality reduction and clustering of different cellular populations. These genes were selected as the intersection of: (i) the 1000 genes with mean expression higher than 0.1 that showed the largest positive biological variance s 2 bio across cells (''highly variable genes''); (ii) genes differently expressed (10% FDR) between MPPs and HSCs based on the bulk RNA-seq, in both PBS and BCG conditions (Table S2) , and (iii) genes differently expressed between myeloid progenitors (MPP3) and lymphoid progenitors (MPP4) based on the bulk RNA-seq data collected by Cabezas-Wallscheid et al. (Cabezas-Wallscheid et al., 2014) . To this list we added Cd34. Dimensionality reduction and alignment of single cells We applied canonical correlation analysis to align cells from both experimental conditions using the scaled expression values of the 101 genes described above using Seurat (Satija et al., 2015) . Using this method, the subspaces of the data matrixes that are maximally correlated are identified, and the projections of each dataset on these subspaces (the canonical vectors, analogous to the principal components in PCA) are calculated.
Thus, we calculated, per each cell, the fraction of the variance that is explained by the n=6 first canonical vectors. Then, we discarded cells where CCA is able to explain less than 50% of the variance that is explained by the same number of principal components in a PCA analysis. This reduces the number of cells to 7,350 cells (5,557 PBS and 1,793 BCG), with 14,711 genes detected in at least 5 of them. The 6 first dimensions of the canonical correlation subspaces were then aligned using the function AlignSubspace from Seurat (Satija et al., 2015) .
Clustering and t-SNE
The different cell clusters were obtained using Seurat's function FindClusters on the n=6 aligned canonical vectors obtained in the previous step. The procedure has the following steps: First, a matrix of Euclidean distances between cells was computed from which we obtained a knn graph. Second, we weighted the links of the graph according to the similarity of their local environments in the graph via Jaccard distances. Finally, cell clusters were obtained, following the Louvain method for modularity maximization with multi-level refinement (option algorithm=2 in Seurat's function FindClusters). We used the default parameters implemented in the function, with the following exceptions: resolution=0.5, n.iter=100, k.param=25. Finally, we run t-distributed stochastic network embedding (t-SNE) to visualize the clustering using RunTSNE, also from Seurat ( Figure 3A) . Clustering validation and classification of different sub-populations To associate the clusters obtained in the previous step to specific sub-populations of LKS + cells, we used the DE results between HSCs and MPPs obtained in bulk RNA-seq data reported in Table S2 . In the PBS group, we obtained 2950 DE genes (10% FDR), and 4963 in BCG, that were then also detected in the scRNA-seq dataset (1628 in the intersection, used henceforth). Then, we compared the average expression values across clusters of this subset of genes that also overlap with the set of ''highly variable genes'' defined before, stratifying them according to the direction of the effect in bulk RNA-seq ( Figure S4C ) This first analysis allowed us to establish a first split between HSCs (first two clusters) and MPPs (clusters three to six). Next, to distinguish between myeloid-biased (MPP3) and lymphoid-biased (MPP4) progenitors, we plotted the average expression values across MPP clusters of the set of ''highly variable genes'' known to be up-and down-regulated in MPP3 with respect to MPP4 (as reported by (Cabezas-Wallscheid et al., 2014) . This analysis allowed us to separate our MPP-clusters into myeloid-biased progenitors (MPP3.C1, MPP3.C2 and MPP3.C3) and lymphoid-biased progenitors (MPP4) ( Figure S4C ).
To further validate our cluster classifications, we performed a number of additional analyses. First, we performed differential expression analyses between our (putative) single-cell clusters of HSC vs MPP, as well as between MPP3 vs MPP4 clusters. This was done using the following linear model:
Where Population represents a dummy variable differentiating HSCs vs MPPs, when analyzing all cells for the split of HSCs vs MPPs; or MPP3 vs MPP4, when only MPPs are analyzed. The results of these tests, which were conducted using lmFit, are available in Table S2 . We obtained 3171 and 3005 DE genes for the contrast MPP-HSC, at 1% FDR in PBS and BCG, respectively, and 932 and 347 DE genes for the comparison MPP3-MPP4 at the same significance level. These results validate that these are transcriptionally distinctive cell populations. Second, we compared the effect sizes of DE genes between clusters in the single cell data to the analogous effects between populations inferred from bulk RNA-seq studies. To this purpose, we defined a set of informative markers for each test (HSC vs MPP or MPP3 vs MPP4) , as the top 100 most differently expressed genes in the bulk RNA-seq that are, at the same time, highly expressed in the single cell dataset (detected in at least 50% of the cells of any of the groups involved in the comparison). We then focused on the subset of those informative markers that are also DE in the single-cell data. In support of our classifications, we found that effect sizes in single cell and bulk RNA-seq data for these genes are highly correlated; and the directionality of the effects is concordant for at least 97% of the cases ( Figure S4D ). Importantly, these correlations appear equally strong for both conditions (PBS and BCG-iv) .
Third, we performed an enrichment analysis that shows that genes differently expressed in our single cell data between the different clusters (e.g., HSCs vs MPPs) were strongly enriched (Odds ratios between 8.7 and 69.6) among the set of principal markers defined above ( Figure S4E ).
Finally, we looked for cluster-specific differences in expression, to identify which genes are the most associated with each of the clusters. To do so, we used, for each cluster, the following model:
where ClusterðiÞ is a dummy variable indicating whether a cell belongs to the ith cluster or not. Through these analyses, whose results are reported in Table S4 , several conclusions arise: On the one hand, regarding the cluster HSC2, we found that Cd9, Cd41 (Itga2b), Pbx1 and, most remarkably, Pf4 ( Figure S4F ) were among the top 10 most up-regulated markers in this cluster, suggesting a clear bias towards Megarkaryocytic progenitors (Calaminus et al., 2012; Nakorn et al., 2003) . Interestingly, the simultaneous up-regulation of these four genes closely matches the expression patterns found in one of the cell clusters described in a recent study by Wilson et al. (Wilson et al., 2015) , (i.e., cluster IIe in their paper) who interpreted it as a population of HSCs already biased towards the megakaryocytic lineage, in accordance to previous studies (Sanjuan-Pla et al., 2013; Yamamoto et al., 2013) .
On the other hand, cluster MPP3.C3 shows a marked bias towards the granulocytic lineage, as evidenced by the fact that the top 4 most up-regulated markers of this cluster are granulocyte-associated genes such as Ctsg, Mpo, Prtn3 and Elane ( Figure S4G ). Within-cluster differential gene expression induced by BCG-iv Finally, we interrogated for DE genes in response to BCG-iv in the single cell-RNAseq dataset. Since one of the putative effects of BCG on HSC phenotypes might be the promotion or arrest of cell quiescence, we used here a linear model where cell cycle is not corrected for, in order to avoid masking the putative effects of BCG on the expression patterns of cell cycle-dependent genes:
The results of these analyses, for each cluster, are reported in Table S4 and summarized in Figure 3B , evidencing the existence of relevant effects within each of the cell clusters identified.
Chip-sequencing
ChIP-seq Data Processing and Differential Peak Analysis We started by trimming adapter sequences and low quality score bases using Trim Galore (http://www.bioinformatics.babraham.ac. uk/projects/trim_galore/). The resulting reads were mapped to the mouse reference genome using STAR with the following options: -runThreadN 12 -readFilesCommand zcat -alignIntronMax 1. Only reads that had a unique alignment were retained and PCR duplicates were further removed using Picard tools (http://broadinstitute.github.io/picard/).
Peaks were first called on ChIP-seq samples (using respective input IPs as a control) using the MACS2 software suite (Zhang et al., 2008) with the added parameters ''-g mm -q 0.05 -keep-dup all''. For comparison between samples, all peaks from each sample were merged to provide one set of combined peaks. For quantification of the combined peaks, we used the bamutils count command from NGSUtils (Breese and Liu, 2013) to count the number of overlapping reads for each sample. To assess differences in levels of histone modification and chromatin accessibility between BCG-iv and PBS-iv samples (prior to Mtb infection), we used limma (Ritchie et al., 2015) . Peaks with low read counts (median log2(cpm) lower than 2 in both conditions) were filtered from the differential analysis. Differential peaks were used to determine the extent to which changes in chromatin at basal state control the signal associated with BCG-related differences in responses to Mtb infection (see Figure 5 ).
Epigenome Data Visualization
Genome browser tracks were created with the genomeCoverageBed command in BEDTools (Quinlan and Hall, 2010) and bedGraphToBigWig utility from UCSC. Tracks were normalized so that each value represents the read count per base pair per 10 million reads. WashU Epigenome Browser (Zhou and Wang, 2012) was implemented for track visualization.
ATAC-sequencing ATAC-seq Data Processing and Footprinting Analysis ATAC-seq reads were trimmed for adapter sequences and low quality score bases and were mapped to the mouse reference genome. Mapping was performed using BWA-MEM (Li and Durbin, 2009) in paired-end mode at default parameters. Only reads that were properly paired and had a unique alignment (mapping quality > 10) were retained. PCR duplicates were removed using Picard tools (http://broadinstitute.github.io/picard/).
To detect TF binding footprints in the ATAC-seq data we used the program Centipede (Pique-Regi et al., 2011) in two steps. In the first step, we determined which transcription factors were active in mouse BMDMs (i.e., had motif instances with footprints) using a subset of high-confidence motif instance (10K) for each TF. Using this reduced set of motifs, we calculated a Z-score corresponding to the PWM effect in the prior probability in Centipede's logistic model. The Z-score corresponds to the b parameter in:
where p 1 represent the prior probability of binding in Centipede's model in motif location l. We considered a TF binding site as active if the estimate was supported at Bonferroni-corrected p < 0.05 (a list of active TFs detected in BMDMs is provided in Table S6 ). We then scanned the entire genome for motif instances matching the original PWM of active TFs, and defined all putative binding sites for these TFs as those showing a footprint supported by a posterior probability > 0.9. Enrichment of TF Binding Sites among classes of DR genes Peaks were first called on ATAC-seq samples using the MACS2 software suite (Zhang et al., 2008) with the added parameters ''-g mm -q 0.05 -keep-dup all''. To assess which peaks of open chromatin harbor which TF binding sites, the putative binding sites (i.e., ATAC-seq footprints) were overlapped to these peaks.
Called peaks were then assigned to a gene with the closest TSS using HOMER annotatePeaks command (Heinz et al., 2010) . Finally, we interrogated about the enrichment of specific TFs binding in the vicinity of genes belonging to our four patterns of differential responses to Mtb infection (enhance/dampened up/down-regulated genes), using Fisher exact test. Complete results of this test are reported in Table S7 .
DATA AND SOFTWARE AVAILABILITY
All data generated in this study (RNA-seq, ChIP-seq and ATAC-seq) are available in GEO database under the accession number GEO: GSE98600. All the Software packages and methods used in this study have been properly detailed and referenced under ''QUANTIFICATION AND STATISTICAL ANALYSIS''. (G andH) Total numbers of CD4 + T cells (G, left graph) , CD8 + T cells (H, left graph) , activated CD4 + T cells (G, right graph) , and activated CD8 + T cells (H, right graph) in the lungs of chimeric mice at four weeks post aerosol Mtb infection (n=5-6/group). (I) Numbers of Mtb in BMDMs prior to adoptive transfer. Macrophages derived from four-week non-or BCG-vaccinated mice were infected with Mtb (H37Rv; MOI of 0.5) and subjected to the CFU assay to assess the initial dose of infection (n=7/group). Mean ± SEM. * p%0.05, ** p%0.01 (1-way ANOVA, 2-way ANOVA).
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